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Protective effect of prostacyclin on postischemic acute renal failure in
the rat. Infusion of prostacyclin (PGI2) reportedly attenuates renal
ischemic injury in the dog and the rat. In the dog, PG!2 is a potent renal
vasodilator; in the rat a direct action on the renal vasculature is not
always apparent. To determine whether or not the protective effect of
PG!2 on postichemic ARF was hemodynamically mediated, studies
were performed in uninephrectomized Sprague—Dawley rats before and
after a 40 minute period of complete renal artery occlusion. In response
to the preischemic infusion of PGI2 for 30 minutes at 160 ng!kg body
wt/min iv. (N = 7), MAP and RBF fell to 86 7% (P< 0.0001) and 84
9% (P <0.05) of baseline values, respectively. RVR initially declined
to 81 9% of baseline values (P < 0.025) but returned to 102 13% of
baseline values prior to the period of ischemia. Following the period of
ischemia, reflow of blood in the rats receiving PGI2 was delayed when
compared to rats not receiving PG!2 (N = 7). RBF returned to only 76
19% of the initial values in PGI2-treated rats (P < 0.01) but to 90
12% of the initial values in rats receiving buffer alone (NS). Observa-
tions made during the ensuing 48 hours in animals treated with either 80(N = 8)or 160 ng!kg/body wt/min (N = 7) for 30 minutes before and four
hours after the period of ischemia indicated that renal function im-
proved to a greater extent in the PGI2-treated animals than in buf-
fer—treated animals (N = 15) as judged by significantly—greater mean
values of V, Uosm, Ucr and Ccr. On the second day after ischemia, C1
was significantly greater in PGI2-treated animals than in the postische-
mic animals receiving buffer alone (77 45 vs. 33 20 pi/min/100 g
body wt; P < 0.05) despite the fact that no differences were found in the
mean values of RBF (3.59 1.08 vs. 3.43 0.32 mI/min/100 body wt.
Blinded analysis of the histological sections revealed significantly less
evidence of tublar epithelial cell necrosis in the PGI2-treated animals (P
< 0.005). The data indicate that the protective effect of PGI2 on the
renal response to ischemic injury in the Sprague—Dawley rat is not
related to changes in RBF or RVR. Instead, the beneficial effect of PG!2
may be a result of cytoprotective properties as has been demonstrated
in other tissues.
In addition to its ability to prevent platelet aggregation,
prostacyclin (PGI2, epoprostenol) is a potent systemic vasodi-
lator and may have cytoprotective properties. Although several
studies have demonstrated that the severity of postischemic
acute renal failure in both the dog and rat may be decreased by
treatment with PG!2 [1—6], the mechanism by which this occurs
has not been established. Infusion of PGI2 results in direct renal
vasodilation in the dog [7—91; it has been suggested that this
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effect is responsible for the improvement in renal function
following ischemic injury. In the rat [10—14], however, it has
been difficult to demonstrate that infusion of PGI2 results in a
significant increase in renal blood flow (RBF) [15]. In fact, an
increase in renal vascular resistance (RVR) has been noted in
response to an intra-aortic infusion of 62 ng/kg/min in rats [161.
At intravenously—administered doses greater than 40 to 80
ng!kg/min, systemic vasodilation and a fall in arterial blood
pressure (MAP) are accompanied by a decrease in RBF [171.
These considerations raise the possibility that the protective
effect of PGI2 on renal ischemic injury is not a consequence of
an increase in RBF.
To examine the effect of high doses on PG!2 on RBF
following ischemic injury to the kidney and to determine if an
increase in RBF or a decrease in RVR was necessary for the
protective effect to be manifested, a series of studies was
performed before and during the 48 hours following a 40-minute
period of renal ischemia. The results indicate that the beneficial
effect of PGI2 is not a result of an increase in the rate and/or
extent of reperfusion of the postischemic kidney and suggest
that other mechanisms are responsible.
Methods
Observations are reported on 50 male Sprague—Dawley rats
that weighed between 275 and 325 gms each. In the first series
of experiments, all animals (N= 14) were fasted overnight but
allowed free access to water. On the day of surgery the animals
were anesthetized with intraperitoneal sodium pentobarbital, 60
mg/kg! body weight, and placed on a heated table that main-
tained body temperature between 37 and 38°C. A tracheostomy
was performed, and a catheter was placed in a jugular vein for
the infusion of 0.85% sodium chloride (at a rate of 40 pilmin)
and the administration of supplemental doses of sodium pento-
barbital. The right kidney was exposed through a flank incision,
the pedicle ligated, and the kidney removed. After the incision
was closed, the left kidney was exposed through an abdominal
incision and the left renal artery was isolated. RBF was
measured with a non-cannulating electromagnetic flow trans-
ducer connected to a square—wave flowmeter and a Hewlett—
Packard recorder (Elkhart, Indiana, USA) [18]. Femoral MAP
was recorded continuously with a Statham P23Db pressure
transducer (Statham Instruments, Oxnard, California, USA)
connected to a Hewlett—Packard recorder.
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After the surgery was complete, MAP and RBF were mea-
sured for 10 mm (Period 1). Thereafter, the animals were
divided into two groups. In the treated group (N = 7), PGI2
(Burroughs Weilcome Co., Research Triangle Park, North
Carolina, USA) was dissolved in glycine buffer and infused
through the catheter in the jugular vein at 160 ng/kg/min (Period
2). After 30 minutes, 10 to 15 units of heparin/l00 g body weight
(1000 units/mi, the Upjohn Company, Inc., Kalamazoo, Mich-
igan, USA) were injected intravenously, and a smooth—surfaced
tension clamp (Schwartz 1-inch clip; Roboz Surgical Instrument
Co., Inc.) was positioned on the left renal artery so that it was
completely occluded. The clamp was removed after 40 minutes.
PG!2 was infused continuously during this time and for an
additional 30 minutes after the release of the clamp (Period 3).
Then, the PG!2 was stopped, and MAP and RBF were moni-
tored for a final 10 minutes (Period 4). At each interval RVR
was calculated according to the equation:
RVR = MAP - MVP/RBF
where MVP is the mean renal venous pressure and is assumed
to be 3 mm Hg. The second group of rats (N = 7) was treated
similarly, but was infused with the glycine buffer alone.
In the second series of experiments, rats (N = 36) were
anesthetized by intraperitoneal injection of sodium pentobarbi-
tal and placed on a heated table A Silastic catheter was placed
in a jugular vein and tunneled subcutaneously to an incision in
the dorsal surface of the neck. The catheter was passed through
a stainless steel spring that was sutured in place. The spring was
attached to a brass swivel, which was attached by a second
catheter to a constant infusion pump. The right kidney was
removed through a flank incision as described above. In the
majority of rats (N = 30) the left renal artery was exposed by a
small midline abdominal incision and it was isolated and com-
pletely occluded for 40 minutes as described above. After
removal of the clamp, the surface of the kidney was observed
and the time of blood reflow — as judged by diffuse capillary
filling — was recorded. In the remaining rats (N = 6) the left
renal artery was exposed and isolated but was not clamped.
Thereafter, the wound was closed, and the animals were placed
in individual metabolic cages. Saline was then infused at
approximately 1 ml/hr for the duration of the experiment. The
animals were not restrained; connection to the brass swivel
allowed free movement in the cages.
In one group of animals, P012 at either 80 (N = 7) or 160 (N
= 8) ng/kg/min was infused for 30 minutes before, during and
for four hours after the period of renal ischemia. Four hours
was selected as the duration of the postischemic infusion of
PGI2 to include the time over which reperfusion injury occurs.
The second group of animals (N = 15) was treated similarly but
received glycine buffer alone. The animals not subjected to
renal ischemia also received glycine buffer alone. All animals
were maintained on their standard rat pellet diet (Purina) and
allowed free access to water. Urine was collected continuously
during two 24-hour periods. Blood samples were obtained at the
end of each period from the tip of the tail. The hematocrit was
measured in heparinized capillary tubes. Plasma and urine
creatinine concentrations (Pcr, and Ucr) were determined by a
modification of the method of Chasson, Grady and Stanley [19].
Creatinine clearance (Car) was calculated for each 24-hour
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Fig. 1. The effects of an infusion of PG!2 (160 ng//cg/min) or glycine
buffer alone on arterial blood pressure, renal blood flow and renal
,'ascular resistance before and after a 40-minute period of complete
renal artery occlusion in uninephrectomized rats. Results are illustrated
as percent of baseline values SEM. Symbols are: (•) control, (0)
PGI2-treated, < 0.05.
pressure method using a Wescor osmometer and osmolar
excretion (UosmV) was calculated. Plasma and urine sodium
concentrations (PNa, UNa) were determined by flame photome-
try (model 480, Corning Medical and Scientific, Midfield, Mas-
sachusetts, USA), and the fractional excretion of sodium (FENa)
was calculated.
At the end of 48 hours, the animals were anesthetized by
intravenous injection of sodium pentobarbital and prepared for
clearance studies. A tracheostomy was performed, and a fern-
oral artery was cannulated for determination of MAP, The left
kidney was exposed through an abdominal incision. The left
ureter was catheterized with PE-lO polyethylene tubing. RBF
was determined as described above. After the surgical proce-
dure was completed, an appropriate amount of 3H-methoxy
inulin (New England Nuclear, Boston, Massachusetts, USA)
was added to the saline infusion. After equilibration for 60
minutes urine was collected in preweighed cups during two
15-minute periods. Midway through each period, a blood sam-
ple was obtained from the tip of the tail for determination of
hematocrit and inulin concentration. Urine and plasma 3H
activities were measured in a liquid scintillation counter (Packard
Instrument Company, Downers Grove, New Jersey, USA).
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Table 1. Effect of infusion of PG!2 (160 ng/kglmin; N = 7) or Buffer alone (N = 7) on arterial blood pressure, renal blood flow and renal
vascular resistance before and after a 40-minute period of complete renal artery occlusion in uninephrectomized rats
Preischemia Postischemia
Period 1 Period 2 Period 3 Period 4
ABPmm hg
Buffer 112 10 109 16 125 23 124 21
PG!2 110 13 90 13 100 13 115 6
P NS <0.025 <0.025 NS
RBF mi/mm per 100g body wt
Buffer 3.82 0.43 3.87 0.38 3.21 0.39 3.36 0.68
PG!2 3.82 0.92 3,13 0.38 2.86 0.74 3.18 0.62
P NS <0.0125 NS NS
RVR mm Hg/mi/mm per 100 g body wt
Buffer 28.33 4,03 27.65 55.86 38.66 3.11 36.28 5.97
PG!2 29.10 5.27 28.66 3.16 36.03 5.23 36.05 5.23
P NS NS NS NS
Table 2. Effects of PGI2 infusion (80 and 160 ng/kg/min) 30 minutes before and four hours after a 40-minute period of complete renal artery
occlusion in uninephrectomized rats
Day Non-ischemic
Postischemic
Buffer P PG!2
Hematocrit % 1
2
41.3 3.8
40.8 3.7
37.5 3.7
37.8 4.09
<0.01
<0.0025
40.8 2.9
42.5 3.3
Serum creatinine mg/dl 1
2
0.3 0.1
0.3 0.1
4.1 0.6
5.1 1.0
NS
<0.025
3.7 0.6
3.7 1.2
Urine volume mi/day/l0O g body wt 1
2
9.5 1.5
7,7 2.6
8.3 4.1
13.0 5.6
<0.05
<0.0025
11.0 4.3
18.9 4.5
Water intake ml/day/100 g body wt 1
2
3.9 3.7
6.5 3.0
6.7 2.4
7.4 3.9
<0.005
<0.005
10.5 4.9
11.8 4.8
Saline infusion ml/day/100 g body wt 1
2
7.2 1.1
5.7 1.7
6.8 1.0
6.4 0.9
NS
NS
7.6 1.0
7.0 1.1
Net in ml/day/I00 g body wt 1
2
1.4 5.2
4.5 3.3
5.1 2.9
0.8 3.9
NS
NS
7.1 5.9
—0.1 3.2
Urine osmolality mOsm/liter 1
2
814 333
1140 374
482 117
464 125
<0.0005
<0.0005
641 75
653 101
Osmolar excretion mOsm/day/100 g body wt 1
2
7.4 2.3
8.3 2.3
4.1 2.5
6.4 4.1
<0.0025
<0.0005
7.0 2.7
12.2 3.0
Urine creatinine mg/dl 1
2
30.1 10.3
33.9 16.7
7.2 2.6
9.1 3.9
NS
<0.05
9.2 3.9
12.3 5.7
Creatinine excretion g/mmn/100 g body wt 1
2
20.0 4.6
17.5 6.8
4.1 2.8
8.2 4.4
<0.025
<0.0005
6.6 2.9
15.1 4.9
U/P creat ratio 1
2
101 50
162 94
1.8 0.8
1.9 1.1
NS
<0.0125
2.6 1.3
4.0 2.5
Creatinine clearance pJ/min/100 g body wt 1
2
667 309
830 466
11 8
18 12
<0.05
<0.0025
18 12
46 28
Results are 1 SD. Reference values obtained from uninephrectomized rats not subjected to ischemic injury also listed.
injury were excised, cleared of perirenal fat, decapsulated, and
fixed in formalin. Kidneys from rats treated with PGI2 or the
glycine buffer alone were coded and prepared for light micros-
copy. Following a blinded histopathologic analysis, the kidneys
were assigned an injury score based on the severity and extent
of the tubular epithelial cell injury. The degree of necrosis was
rated as minimal, mild, moderate, or marked and assigned a
value form 1 to 4.
For analyses of significance, paired and unpaired t=tests and
linear regression by least—squares were performed for the
functional studies. Differences in the histological studies were
evaluated with the Wilcoxon non-paired rank sum test. A P
value greater than 0.05 was considered to be not statistically
significant (NS). Values are presented as means SD unless
otherwise indicated.
Results
Absolute mean values of MAP, RBF, and RVR observed in
glycine buffer and PGI2-treated animals at the end of the two
preischemic and the two postischemic periods are listed in
Table 1. The mean values, expressed as percent of baseline, are
illustrated in Figure 1. Before the infusion of PG!2 or glycine
buffer alone (Period 1), there were no significant differences in
the baseline values of MAP, RBF, or RVR. In response to the
PGI2 infusion (Period 2), MAP fell to 73 12% of baseline at 5
minutes (P < 0.001) and then returned to 86 7% of baseline
prior to the period of ischemia (P < 0.001). In association with
the decline in MAP, RBF fell to 88 7% of baseline at 5
minutes (P < 0.025) and did not change thereafter despite the
increase in MAP. Before the period of ischemia, RBF was 84 ±
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Table 3. Results of clearance studies in untreated and P012-treated, unilaterally nephrectomized rats 48 hours following a 40-minute period of
complete renal artery occlusion
Nonischemic
Postischemic
Untreated P P012
Arterial blood pressure mm Hg 121 13 102 18 <0.05 118 10
Renal blood flow ml/min/100 g body wt 4.12 0.79 3.43 0.32 NS 3.59 1.08
Renal vascular resistance mm Hg/mi! 29,64 7.21 29.98 7.75 NS 34.01 8.19
min/lOO g body wt
Urine/plasma inulin ratio 123.4 42.8 5.0 1.4 NS 6.0 3.2
Urine flow rate ui/min!100 g body wt 6.5 4.1 6.9 4.6 <0.05 12.9 4.6
Insulin clearance ui!min!100 g body WI 653 132 33 20 <0.05 77 45
Nofanimals 6 15 15
Results I so. Reference values obtained from uninephrectomized rats not subjected to ischemic injury also listed.
Fig. 2. Light micrograph of representative sections demonstrating a) minimal (score = 1) and b) mild (score = 2) tubular necrosis from
prostacyclin—treated animals 48 hours after ischemic injury. Tubular dilatation, atrophy and casts are confined mainly to the inner cortex
(hematoxylin and eosin, x 120).
9% of baseline (P < 0.025). RVR exhibited an initial fall to 81
9% of baseline at 5 minutes (P < 0.025). This was followed by
a gradual increase so that prior to the period of ischemia, RVR
was 102 13% of baseline (NS). These values remained
constant in the animals receiving the glycine buffer alone.
Upon release of the renal artery clamp (Period 3), there were
significant differences in the pattern of reflow (Fig. 1) that were
most evident during the first 5 minutes. During this time, the
increase in RBF in the PGI2-treated animals was delayed when
compared to the animals receiving the glycine buffer alone. In
part, this was a result of a lower MAP in the P012-treated
animals and in part a result of a higher RVR.
Thirty minutes after the release of the renal artery clamp in
the PGI2-treated animals, RBF had only returned to 76 19%
(P < 0.01) of baseline; in the animals receiving the glycine
buffer alone, RBF returned to 90 12% of baseline (NS). When
the PGI2 infusion was stopped (Period 4), RBF increased to 89
15% of baseline (NS). This value was not significantly
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Fig. 3. Light micrograph of representative sections demonstrating a) moderate (score = 3) and b) marked (score = 4) tubular necrosis from
buffer—treated animals 48 hours after ischemic injury. Tubular dilatation, atrophy and casts involve the full width of the cortex (hematoxylin and
eosin, x 120).
different from that observed in the animals receiving the glycin
buffer alone. The increase in RBF that occurred when the PGI2
infusion was stopped resulted from an increase in MAP, as
RVR remained constant.
The changes in renal function that occurred during the two
days of observations are listed in Table 2. Also listed are the
results obtained in unilaterally nephrectomized rats not sub-
jected to a period of renal ischemia. No significant differences
were found in the response to 80 or 160 ng/kg body weight/mm,
and the results are combined. Inspection of the kidney surface
during the time of reflow demonstrated a delay in capillary
filling of PGI2-treated animals compared with animals receiving
glycine buffer alone (3.4 1.2 vs. 1.9 0.9 mm; P < 0.0005).
This was consistent with the differences in the pattern of reflow
noted above and illustrated in Figure 1. Over the 48-hour period
of observation following renal ischemia, urine output (V) was
41% greater in PGI2-treated animals than in the animals given
glycine buffer alone. This was accompanied by a 59% greater
intake of water, so the net difference between intake and output
in the two groups was similar, Judged by differences in the
hematocrit, there was no evidence of hemodilution in the
PGI2-treated animals. In fact, on both days, the hematocrit was
significantly less in the animals receiving the glycine buffer
alone.
In PGI2-treated animals, the mean values of Uosm on both the
first and second postischemic day were significantly greater than
those animals receiving the glycine buffer alone. The mean values
Of UCr in the two groups reflected the differences in Uosm and were
significantly greater on day 2 in the PGI2-treated animals. As a
result of the higher values of V, Uosm and Ucr, the mean values of
UosmV and UcrV were significantly greater in the PGI2-treated
animals than in the animals receiving the glycine buffer alone on
both the first and second postischemic days. Although a significant
difference in the mean values of SCr was not present on day I, the
mean value of the CCr was 64% greater in the PGI2-treated
animals. A significant difference in the mean values of Scr was
evident on day 2, and at this time the mean value of the CCr was
156% greater in the PGI2-treated animals.
Results of the clearance studies on day 2 are listed in Table 3.
The mean values for MAP, RBF, and RVR in glycine buffer and
PGI2-treated rats were similar with mean MAP slightly higher in
the PG!2 group. In the PGI2-treated rats, the mean value of V
and C were 87% and 148% greater than the respective values
found in the animals receiving the glycine buffer alone. These
differences were similar to the differences in V and CCr noted
previously.
The histologic examination of all kidneys from the glycine
buffer and PGI2-treated animals showed evidence of ischemic
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Fig. 4. Light micrographs at higher magnification of sections from a) prostacyclin—treated and b) buffer—treated animals 48 hours after ischemic
injury.In rats given prostacyclin, tubular lumena are filled with proteinaceous material. Basement membranes are lined with cuboidal and
rhomboidal shaped epithelial cells. Nuclei in the majority of the tubular epithelial cells are distinct and some contain mitotic figures. In rats given
buffer alone, tubular epithelial cell damage is more severe. Tubular lumena contain remains of tubular epithelial cells while segments of the
basement membrane are uncovered. In many areas necrosis of tubular epithelial cells has progressed to the point that cell boundaries and
intracellular structures cannot be recognized. (hematoxylin and eosin, x340).
injury and the presence of proteinaceous and granular cast
formation. A minimal amount of intratubular mineralization
with areas of tubular regeneration was observed equally in both
groups. Based on the assigned severity scores, kidneys from the
animals receiving glycine buffer alone exhibited significantly
greater tubular epithelial cell necrosis than did the kidneys from
the PGI2-treated animals (3.27 0.79 vs. 2.27 0.59; P <
0.005). In addition, the injury involved the full width of the
cortex in 81.8% (9 of!!) of the control kidneys and only 33,3%
(5 of 15) of the PGI3-treated kidneys. Representative photomi-
crographs are shown in Figures 2 through 4.
An inverse relationship was found between the severity of the
tubular epithelial cell necrosis in individual animals and the
corresponding Ccr (r = 0.643; P < 0.001) while a positive
correlation was found when the histologic score was compared
to the corresponding FENa (R = 0.513; P <0.005).
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Discussion
These data indicate the protective effect of PGI2 is not a result
of renal vasodilation and an increase in RBF. Compared with
animals receiving glycine buffer alone, those treated with PGI2
had higher Cr and C1 48 hours following ischemic injury in
associations with greater V and less severe derangements in
tubular function as indicated by mean values of Uosm and UCr.
Examination of histologic sections revealed that the degree of
tubular epithelial cell injury could be correlated with reduction
in Ccr and was less severe in the animals treated with PGI2.
These observations are consistent with the hypothesis that the
beneficial effect of PGI2 is a result of a protective action on renal
tubular epithelial cells. It should be emphasized that although
Cr and C1 in the PGI2 treated animals remained severely
depressed when compared to the values obtained in animals not
subjected to renal ischemia, the reduction in tubular epithelial
cell injury was substantial. This supports the notion that rela-
tively mild degrees of anatomical injury may be associated with
severe functional impairment.
Previous studies concerning the effect of PG!2 on postische-
mic ARF have been performed in both the dog and rat. In the
dog, PG!2 at doses of 0.25 jsg/kg body weight/mm administered
prior to autotransplantation [1] or renal pedicle cross clamping
[2] significantly minimized the extent of ischemic injury. In both
studies, prior vasodilation was considered a contributor to the
protective effect. In the rat, doses as high as 0.5 g given
directly into the renal artery [3, 4] and as low as 8 ng/kg body
weight/mm infused intravenously in both hydropenic and vol-
ume expanded animals [5] have had a protective effect. While
these studies relate to the effect of exogenously—administered
PGI2, evidence also exists for a protective role of endogenous
PGI2. Observations made in the rat show that the beneficial
effect of thromboxane synthetase inhibition on postischemic
ARF is more closely related to the associated increase in PGI2
synthesis rather than a direct result of the inhibition of throm-
boxane production [6].
It has been reported that a more rapid return of blood flow in
the immediate postischemic period may be accompanied by an
initial increase in glomerular filtration rate, urine flow, and
solute excretion [2]. PG!2 is a potent systemic vasodilator and,
in the dog, is capable of directly reducing RVR [7—9]. In the rat,
it has been suggested that PGI2 also has a direct renal vasodila-
tory action [10—14] although not all agree [10, 16]. Confounding
the issue are the observations that PGI2 stimulates renin release
in intact animals [7] and in preparations of isolated glomeruli
[21]. Also, strain differences may exist in the renal vascular
response to PG!2. Notably, when Sprague—Dawley rats are
pretreated with saralasin, the intra-aortic infusion of PGI2 at a
dose sufficient to produce significant systemic vasodilation (3.6
gIkg/hr), does not alter RVR [15]. When PGI2 is infused
intravenously in rats at much larger doses (1 to 1265 ng/lOO g
body weight/mm), a fall in MAP is accompanied by a decline in
RVR without a change in RBF. The decrease in RVR appears to
be a result of the autoregulatory response to a decrease in
perfusion pressure rather than a direct action of PG!2 [17].
In this study, the infusion of PG!2 resulted in a fall of MAP
and RBF. When the PGI2 infusion was stopped, MAP and RBF
rose to levels similar to those observed in animals not treated
with PG!2. During the initial postischemic period, the return of
RBF was more rapid and of greater magnitude in control
animals than in animals treated with PGI2. The reason for the
delay was not entirely due to a lower perfusion pressure in the
PGI2-treated animals in that RVR during the very early postis-
chemic period was significantly greater in this group. It is
possible that PGI2-stimulated renin release contributed to these
differences. When RBF was measured 48 hours after the insult,
differences were not found between the two groups of animals.
Thus, the beneficial effect of PG!2 was not related to an increase
in REF in the immediate postischemic period, or to a greater
rate of perfusion as recovery occurred.
PGI2 is a potent inhibitor of platelet aggregation. It is possible
that platelet aggregation accompanies renal ischemic injury and
that the subsequent release of vasoactive substances contrib-
utes to the increase in RVR and poor perfusion of the postis-
chemic kidney. In our study, PGI2 was administered in doses
sufficient to inhibit platelet function. As indicated above, this
was not reflected in an improvement in RBF or RVR. A
prominent feature of ischemic acute renal failure in the rat is the
appearance of marked medullary hyperemia, which appears to
be due to the accumulation of aggregated erythrocytes in inner
stripe capillaries. The magnitude of these anatomical changes
can be directly related to the severity of the functional abnor-
malities. The vascular congestion does not appear to be a result
of fibrin deposition or platelet aggregation but rather has been
related to the occlusion of vasa rectae by erythrocytes [22]. In
this regard, it has been observed that a reduction in the
hematocrit is associated with less severe injury following ische-
mic insults [23]. The hematocrit on both days 1 and 2 was
significantly higher in the PGI2-treated rats in our study.
A number of diverse studies have indicated that PG!2 pos-
sesses cytoprotective properties. Lefer et al [24] were the first
to note its beneficial effect in acute myocardial ischemia. Others
have demonstrated that various prostaglandins exert a protec-
tive effect on the gastric mucosa [25, 26]. PG!2 has also been
shown to reduce the breakdown of membrane phosphatides
[27], preserve the integrity of platelets during storage [28],
protect hepatic cells against ischemic [29] and toxic [30] injury,
and modify the changes of acute experimental pancreatitis in
dogs [31]. It has been suggested that the mechanism by which
PGI2 exerts its cytoprotective action may be related to changes
in membrane transport processes, increases in tissue levels of
adenosine triphosphate and other cyclic nucleotides [29, 32], or
alterations in the enzyme systems generating toxic—free radical
anions [33]. The latter mechanism may involve a direct cellular
action [34] or may be a result of the inhibition of oxygen
centered radical formation from neutrophils [35—37]. Other
undefined mechanisms of cell preservation may also be influ-
enced by PG!2 [38]. Alternatively, prostanoids may accelerate
certain restorative metabolic and structural processes rather
than minimize the role of free—radicals and lipoperoxides [30].
It has been demonstrated that the administration of specific
free—radical scavengers [39] or treatment with calcium chan-
nd—blocking agents [40] reduces the amount of tubular epithe-
hal cell injury associated with renal ischemia. Moreover, ATP-
MgCl2 solutions [41] have been shown to minimize ischemic
damage and/or promote early recovery. The results of the
present study support the concept that PG!2 has cytoprotective
properties that influence the response to ischemic injury. Re-
cently, studies performed in the isolated perfused rat kidney
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have indicated that the Si and S2 segments of the proximal
tubule, the S3 segment of the proximal tubule and the medullary
thick ascending limb differ in their sensitivity to hypoxic injury;
also, agents that influence the degree of injury in one segment
may not be as effective in other segments [42, 43]. Although we
did not examine the specific nephron segment at which PG!2
may have exerted its protective effects, the observation that
attenuation of the ischemic injury in the PGI2-treated animals
was most apparent in the outer cortex suggests PGI2 may have
had an effect on proximal tubular epithelial cells. However, the
greater values of UOsm and UCr are consistent with a more distal
effect.
Finally, it is possible that other cytoprotective agents may
interact with PGI2. For example, it has been reported that
calcium channel—blocking agents lead to a stimulation of PG!2
production [441. Alternatively, the adverse effects of various
nonsteroidal anti-inflammatory drugs may, in part, be related to
an inhibition of PGI2 formation and absence of its cytoprotec-
tive functions.
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